INS and Hyperglycemia: Dual GIP and GLP-1 receptor co-activation enhances insulin secretion by 20–30% more than the single administration, improves insulin sensitivity, and reduces glucagon secretion, and the reduction in hyperglycemia additionally reduces the resistance to GIP [68].